Waldenstrom macroglobulinemia cells devoid of BTK(C481S) or CXCR4(WHIM-like) mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment

Although ibrutinib is highly effective in Waldenstrom macroglobulinemia (WM), no complete remissions in WM patients treated with ibrutinib have been reported to date. Moreover, ibrutinib-resistant disease is being steadily reported and is associated with dismal clinical outcome (overall survival of...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Blood Cancer J
Main Authors: Paulus, A, Akhtar, S, Yousaf, H, Manna, A, Paulus, S M, Bashir, Y, Caulfield, T R, Kuranz-Blake, M, Chitta, K, Wang, X, Asmann, Y, Hudec, R, Springer, W, Ailawadhi, S, Chanan-Khan, A
פורמט: Artigo
שפה:Inglês
יצא לאור: Nature Publishing Group 2017
נושאים:
Original Article
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC5518884/
https://ncbi.nlm.nih.gov/pubmed/28548645
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bcj.2017.40
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים